Boosting antibody-dependant cellular cytotoxicity against tumor cells with a CD137 stimulatory antibody

Stimulation of natural killer cells with a CD137-specific antibody enhances trastuzumab efficacy in xenotransplant models of breast cancer

(2012) Holbrook E. Kohrt et al.   JOURNAL OF CLINICAL INVESTIGATION

Immunomodulating antibodies and drugs for the treatment of hematological malignancies

(2011) Roch Houot et al.   CANCER AND METASTASIS REVIEWS

Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma

(2011) Caroline Robert et al.   NEW ENGLAND JOURNAL OF MEDICINE

CD137 stimulation enhances the antilymphoma activity of anti-CD20 antibodies

(2010) H. E. Kohrt et al.   BLOOD

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

(2010) F. Stephen Hodi et al.   NEW ENGLAND JOURNAL OF MEDICINE

Immunoglobulin G Fragment C Receptor Polymorphisms and Clinical Efficacy of Trastuzumab-Based Therapy in Patients With HER-2/neu–Positive Metastatic Breast Cancer

(2008) Antonino Musolino et al.   JOURNAL OF CLINICAL ONCOLOGY

Multi-layered action mechanisms of CD137 (4-1BB)-targeted immunotherapies

(2008) Ignacio Melero et al.   TRENDS IN PHARMACOLOGICAL SCIENCES